Therma Bright Submits Updated FDA 510K Application Requesting Correction of Venowave Device's Intended Use, Labeling, and Descri...

Published on September 7, 2023

9/7/2023

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies



(Feed generated with FetchRSS)
Continue reading on website
Other news

PharmAla Begins Trading on OTCQB

September 6, 2023
VANCOUVER, BC — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is pleased to announce that it has qualified for trading on the OTCQB Venture Market (the “OTCQB”) in the United States operated by the OTC Markets Group Inc. and the C

Vaxart norovirus vaccine fails to stop symptoms in midphase test but hits on other endpoints

September 7, 2023
Vaxart is still looking a little queasy. The biotech delivered mixed data on its oral monovalent norovirus vaccine candidate, with the failure to cut acute gastroenteritis in the challenge study ensuring a muted response from investors despite successes on other endpoints. For the midphase challenge study, investigators randomized people to receive VXA-G1.1-NN, an adenoviral-vector based norovirus